Search - tctmd.com

Displaying 401 - 420 of 480

Sort: Relevancy | Date

Presentation TCT 2013

A Cost Benefit Analysis of Left Atrial Appendage Closure Versus Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: Vivek Y. Reddy

October 29, 2013

Presentation TCT 2013

Treatment Strategies in Patients with Atrial Fibrillation and Valvular Heart Disease

Presenter: Ted Feldman

October 29, 2013

Presentation TCT 2013

The Need for Screening for Atrial Fibrillation

Presenter: David Albert

October 29, 2013

Presentation TCT 2013

Silent Atrial Fibrillation: An Under-Appreciated Threat

Presenter: Taya Glotzer

October 29, 2013

Presentation TCT 2013

Profile of Patients with Atrial Fibrillation in 2013: From the Highly Symptomatic Athlete to the Asymptomatic 85-Year-Old

Presenter: Mintu Turakhia

October 29, 2013

Presentation TCT 2013

Long term follow up of 134 patients with non valvular atrial fibrillation and contraindications to oral anticoagulation therapy, treated with the Ampatzer Cardiac Plug Device for LAA

Presenter: Miroslava Stolcova

October 29, 2013

Presentation TCT 2013

Introduction: Multifaceted Approaches to Atrial Fibrillation: From Drugs to Ablation to Left Atrial Appendage Closure

Presenter: Vivek Reddy

October 29, 2013

Presentation TCT 2013

Acute Coronary Syndrome and Atrial Fibrillation: 1 + 1 = 5

Presenter: C. Michael Gibson

October 29, 2013

Presentation TCT 2013

Case Presentation: LAA Exclusion in a Patient With Atrial Fibrillation

Presenter: Evgeny Merkulov

October 28, 2013

Presentation TCT 2013

Stroke, Bleeding and Risk Scores in Atrial Fibrillation (with and without Anticoagulation)

Presenter: Stefan Bertog

October 27, 2013

Presentation TCT 2013

Multicenter Experience with the ACP for Stroke Prevention in Atrial Fibrillation

Presenter: Apostolos Tzikas

October 27, 2013

Presentation TCT 2013

Management of Patients with Atrial Fibrillation and Stents

Presenter: Neal Kleiman

October 27, 2013

Presentation TCT 2013

LAA Closure in Valvular Atrial Fibrillation (and TAVR Patients): Rationale and Results

Presenter: Samir Kapadia

October 27, 2013

Presentation Scripps 2013

Left Atrial Appendage Closure for Atrial Fibrillation: Current Status

Presenter: Matthew J. Price

October 03, 2013

Presentation

High Sensitivity Troponin T and Risk Stratification in Patients with A-fib on Apixaban or Warfarin

Presenter: Ziad Hijazi

October 02, 2013

Presentation ESC 2013

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Presenter: Alvaro Avezum

September 03, 2013

Presentation

Atrial Fibrillation in MI Patients: Impact on Health Care Utilization

Presenter: A.M. Chamberlain

August 27, 2013

Presentation

Higher Persistence in Newly Diagnosed Nonvalvular A-fib Patients Treated with Dabigatran vs. Warfarin

Presenter: M. Zalesak

August 12, 2013

Presentation

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

Presenter: David Garcia

August 05, 2013

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

Advertisement

A Cost Benefit Analysis of Left Atrial Appendage Closure Versus Warfarin for Stroke Prevention in Atrial Fibrillation

Treatment Strategies in Patients with Atrial Fibrillation and Valvular Heart Disease

The Need for Screening for Atrial Fibrillation

Silent Atrial Fibrillation: An Under-Appreciated Threat

Profile of Patients with Atrial Fibrillation in 2013: From the Highly Symptomatic Athlete to the Asymptomatic 85-Year-Old

Long term follow up of 134 patients with non valvular atrial fibrillation and contraindications to oral anticoagulation therapy, treated with the Ampatzer Cardiac Plug Device for LAA

Introduction: Multifaceted Approaches to Atrial Fibrillation: From Drugs to Ablation to Left Atrial Appendage Closure

Acute Coronary Syndrome and Atrial Fibrillation: 1 + 1 = 5

Case Presentation: LAA Exclusion in a Patient With Atrial Fibrillation

Stroke, Bleeding and Risk Scores in Atrial Fibrillation (with and without Anticoagulation)

Multicenter Experience with the ACP for Stroke Prevention in Atrial Fibrillation

Management of Patients with Atrial Fibrillation and Stents

LAA Closure in Valvular Atrial Fibrillation (and TAVR Patients): Rationale and Results

Left Atrial Appendage Closure for Atrial Fibrillation: Current Status

High Sensitivity Troponin T and Risk Stratification in Patients with A-fib on Apixaban or Warfarin

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Atrial Fibrillation in MI Patients: Impact on Health Care Utilization

Higher Persistence in Newly Diagnosed Nonvalvular A-fib Patients Treated with Dabigatran vs. Warfarin

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content